In an analysis of outcomes reported in the Journal of Clinical Oncology, men who were diagnosed with lymph node-positive prostate cancer (no bone involvement) who went on to receive targeted radiation (adjuvant radiotherapy) enjoyed a survival benefit over those individuals who did not have this therapy. This finding was specifically for men with both low-volume [...]
I have been informed that it is now possible for men in need of the treatment Xofigo to obtain it without having to pay any co-pays. The program that is making this possible is called Xofigo Access Services and is designed to make Xofigo available for men with a commercial medical insurance policy (not medicaid [...]
Presented in a poster at the recent European Society of Medical Oncologist (ESMO) there was a data update of the phase 3 clinical trial (CA184-043) which evaluated overall survival (OS) in men having radiotherapy (RT) followed by either the immunologic drug Ipilimumab (Ipi) or with a placebo. Initially, this trial did not meet its endpoint [...]
In a new study it was shown that smoking doubles the chances that a prostate cancer survivor will have the cancer spread and that he would die from the cancer. Study co-author Dr. Michael Zelefsky, Vice Chair of Clinical Research in the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center said, "Basically we [...]
It was recently discovered that if hormone therapy (ADT) is added to radiation cancer deaths are lowered by nearly 50 % in men with locally advanced prostate cancer aged 76 to 85 compared to men who only received hormone therapy. Prior studies have shown that 40% of men with aggressive prostate cancers are treated with [...]
There was a recent Norwegian study which reviewed the impact of salvage external beam radiotherapy (EBRT) on post-prostatectomy patients. They evaluated long-term follow-up on biochemical-free recurrence (PSA only recurrence) (BFR) and metastatic-free survival. He study also described the pathological and clinical predictors of outcome. The study was conducted between 1987–2010. It included 76 men with [...]
In a poster presentation at the recent European Society of Medical Oncologists (ESMO) there was a very interesting poster presented updating a phase 3 clinical trial (CA184-043) which evaluated the overall survival (OS) with radiotherapy (RT) followed by either the immunologic drug Ipilimumab (Ipi) or with a placebo. This trial did not meet its endpoint [...]
It would be of great advantage to us if we were able to improve the early detection of responders to salvage external beam radiotherapy (RT) after failed radical prostatectomy (RP). Early detection would allow us to make earlier treatment decisions which should provide for better results. In an attempt to better improve our understanding of [...]
The good news for us is that the survival of men diagnosed with prostate cancer has improved over time. The current 10-year relative survival rate is 99.7%! However, the long survival of men who have prostate cancer raises questions about their risk of a second primary cancer and the need for continued surveillance. A very [...]
Oligometastasis can be described as a state of limited metastatic disease following failed primary treatment or even prostate cancer as it is first diagnosed. Many doctors believe that it is amenable to aggressive local therapy to achieve long-term survival. In a review designed to explore the role of ablative radiotherapy and surgical management of oligo-metastatic [...]
